PARIS – Carthera SAS, of Paris, has obtained a $2.4 million grant and $12.5 million equity investment from the European Innovation Council (EIC) for the development of its ultrasound-based medical device for treating glioblastoma.

RNAi therapeutics specialist Sirnaomics Inc. has wrapped up a $105 million series D financing that will support ongoing clinical development of its cancer and fibrotic disease programs plus work on early stage programs targeting metabolic disease and viral infections. But with both new and existing investors jumping in, the company is also preparing for something bigger: its next phase of growth, including a near-term IPO.

HONG KONG – Shanghai, China-based Immuneonco Biopharmaceuticals Co. Ltd. bagged $25 million in series B financing in October. The funding will mainly support the companies’ immunotherapies, which include IMM-01 and IMM-0306, both of which target CD47.

PERTH, Australia – Azura Ophthalmics Ltd. raised a $20 million series C round with existing investors, including Brandon Capital’s Medical Research Commercialization Fund (MRCF), Orbimed, TPG Biotech and Ganot Capital.

Neuromod Devices Ltd., which is developing an at-home, self-managed treatment for tinnitus, closed a €10.5 million (US$12.4 million) series B financing led by majority investor Fountain Healthcare Partners. The funds are earmarked for expanding European commercialization of the Lenire tinnitus treatment device, to scale up manufacturing, progress U.S. FDA regulatory approval and pursue opportunities with the U.S. Department of Veterans Affairs (VA).